She has personally tested nearly 500 bags, jeans, bras, shoes, and more. We’ve added two new white T-shirts worth considering, Uniqlo’s Crew Neck T-Shirt and Mini T-Shirt. A great white T ...

ABBV-969 is under clinical development by AbbVie and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

This discount is shown at checkout, if applicable. AbbVie is slated to buy oral peptide developer Nimble Therapeutics for $200 million, with the potential for a milestone payment. Nimble was spun ...

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...

“These harms are more than speculative,” he added. The preliminary injunction means West Virginia is blocked from enforcing S.B. 325 against Novartis and AbbVie while the cases play out. The industry ...

AbbVie, a drug company based in North Chicago, Illinois, is paying $200 million to acquire Madison-based Nimble Therapeutics, which is developing an oral therapy that could treat psoriasis and ...

The acquisition of Nimble Therapeutics will grant AbbVie access to a pipeline of oral peptide drugs for the treatment of immune diseases including psoriasis and inflammatory bowel disease AbbVie and ...

According to a press release, AbbVie, the acquiring company, said the move aims to accelerate the development of Nimble's innovative oral therapies designed to treat psoriasis and inflammatory ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...